The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Results of a phase 3 study of IVO vs IO for previously untreated older patients (pts) with chronic lymphocytic leukemia (CLL) and impact of COVID-19 (Alliance).
 
Jennifer Ann Woyach
Consulting or Advisory Role - AstraZeneca; Beigene; Genentech; Janssen; Loxo; Newave Pharmaceutical; Pharmacyclics
Research Funding - Janssen; Karyopharm Therapeutics; MorphoSys; Schrodinger
 
Jun Yin
Employment - Mayo Clinic
 
Jennifer R. Brown
Consulting or Advisory Role - Abbvie; Acerta/Astra-Zeneca; BeiGene; Bristol-Myers Squibb/Celgene/Juno; Catapult Therapeutics; Genentech/Roche; HUTCHMED; iOnctura; Janssen; Lilly; MEI Pharma; MorphoSys; Novartis; Pharmacyclics
Research Funding - BeiGene (Inst); Gilead Sciences (Inst); Loxo/Lilly (Inst); MEI Pharma (Inst); Secura Bio (Inst); Sun Pharma (Inst); TG Therapeutics (Inst)
 
Shira Dinner
Honoraria - Kite, a Gilead company; Novartis; Pfizer
Consulting or Advisory Role - Kite, a Gilead company; Novartis; Pfizer
Research Funding - Cellectis; Gilead/Forty Seven; MEI Pharma; Novartis; SERVIER
 
Gerard Lozanski
Research Funding - Genentech (Inst); Novartis (Inst)
 
Richard F. Little
No Relationships to Disclose
 
Cecelia Miller
No Relationships to Disclose
 
Vijay Kumar Damarla
No Relationships to Disclose
 
Steve E. Coutre
No Relationships to Disclose
 
Wei Ding
Consulting or Advisory Role - Alexion Pharmaceuticals (Inst); BeiGene (Inst); Merck (Inst); Octapharma USA (Inst)
Research Funding - Abbvie (Inst); AstraZeneca (Inst); BeiGene (Inst); DTRM (Inst); Merck (Inst); Octapharma USA (Inst)
 
Brian T Hill
Honoraria - Abbvie; AstraZeneca; Bayer; BeiGene; Celgene; Epizyme; Genentech; Gilead Sciences; Karyopharm Therapeutics; MorphoSys; Novartis; Novartis; Pfizer; Pharmacyclics
Consulting or Advisory Role - Abbvie; AstraZeneca; BeiGene; Epizyme; Genentech; Gilead Sciences; Karyopharm Therapeutics; MorphoSys; Novartis
Research Funding - Abbvie (Inst); Amgen (Inst); Celgene (Inst); Genentech (Inst); Karyopharm Therapeutics (Inst); Kite/Gilead (Inst); Takeda (Inst); TG Therapeutics (Inst)
 
Gabriela Perez Burbano
No Relationships to Disclose
 
Amy S. Ruppert
Employment - Lilly O.
 
Anna K. M. Wall
No Relationships to Disclose
 
Diane Feldman
No Relationships to Disclose
 
Elie G. Dib
Other Relationship - Genentech (Inst); Merck (Inst)
 
Harry Paul Erba
Consulting or Advisory Role - Abbvie/Genentech; Agios; Amgen; Astellas Pharma; Bristol-Myers Squibb/Celgene; Celgene; Daiichi Sankyo; Glycomimetics; Immunogen; Incyte; Janssen Oncology; Jazz Pharmaceuticals; Kura Oncology; Macrogenics; Novartis; Pfizer; Sumitomo Dainippon Pharma Oncology; Takeda; Trillium Therapeutics
Speakers' Bureau - Abbvie; Agios; Bristol Myers Squibb Foundation; Incyte; Jazz Pharmaceuticals; Novartis; SERVIER
Research Funding - Abbvie (Inst); Abbvie (Inst); Agios (Inst); ALX Oncology (Inst); Amgen (Inst); Aptose Biosciences (Inst); Daiichi Sankyo (Inst); FORMA Therapeutics (Inst); Gilead/Forty Seven (Inst); Glycomimetics (Inst); Immunogen (Inst); Jazz Pharmaceuticals (Inst); Macrogenics (Inst); Novartis (Inst); PTC Therapeutics (Inst); SERVIER; Sumitomo Dainippon Pharma Oncology (Inst)
Other Relationship - Bristol-Myers Squibb/Celgene; Celgene; Glycomimetics
(OPTIONAL) Uncompensated Relationships - Daiichi Sankyo
 
Mark Robert Litzow
Consulting or Advisory Role - Jazz Pharmaceuticals
Research Funding - Abbvie; Actinium Pharmaceuticals; Amgen; Astellas Pharma; Novartis; Pluristem Therapeutics; Syndax
Other Relationship - Biosight
 
Richard M. Stone
Honoraria - DAVA Pharmaceuticals; Medscape; Prime Oncology; Research to Practice
Consulting or Advisory Role - Abbvie; Actinium Pharmaceuticals; Amgen; Aprea Therapeutics; Aptevo Therapeutics; Arog; AvenCell; BerGenBio; Boston Pharmaceuticals; Bristol Myers Squibb; CTI BioPharma Corp; ElevateBio; Epizyme; Foghorn Therapeutics; Gemoab; GlaxoSmithKline; Innate Pharma; Janssen; Jazz Pharmaceuticals; Kura Oncology; Novartis; Onconova Therapeutics; Rigel; Syndax; Syntrix Biosystems; Syros Pharmaceuticals; Takeda
Research Funding - Abbvie/Genentech (Inst); Agios (Inst); Novartis (Inst)
 
John C. Byrd
Stock and Other Ownership Interests - Vincerx Pharma
Honoraria - AstraZeneca; Novartis; Novartis; Syndax; Trillium Therapeutics
Consulting or Advisory Role - AstraZeneca; Janssen; Kura Oncology; Newave Pharmaceutical; Novartis; Syndax
Research Funding - Acerta Pharma (Inst); Pharmacyclics (Inst); Zencor
Patents, Royalties, Other Intellectual Property - OSU Patents (Inst)
Travel, Accommodations, Expenses - Gilead Sciences; Janssen; Novartis; Pharmacyclics; TG Therapeutics